Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;34(8):e13113.
doi: 10.1111/jne.13113. Epub 2022 Mar 21.

Long-term morbidity and mortality in patients with Cushing's syndrome

Leah T Braun  1 , Frederick Vogel  1 , Martin Reincke  1
Affiliations
Review

Long-term morbidity and mortality in patients with Cushing's syndrome

Leah T Braun et al. J Neuroendocrinol. 2022 Aug.

Abstract

Increased multisystem morbidity and mortality in patients with Cushing's syndrome comprise clinical problems and challenges, both at the time of diagnosis and in remission. Relevant comorbidities and clinical problems include hypertension, diabetes, overweight, myopathy and a high risk for acute complications such as infections and venous thrombembolism. Although there are therapy recommendations for most of these comorbidities, there is a lack of large, prospective studies to confirm and optimise them. Mortality is especially high during active disease and within the first year after diagnosis, as a result of cardiovascular events, infections and suicide. All in all, interdisciplinary therapy management is important for reducing morbidity and mortality over the long-term.

Keywords: ACTH; Cushing's disease; cortisol; hypercortisolism.

PubMed Disclaimer

References

REFERENCES

    1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (Pituitary basophilism). Bull Johns Hopkins Hosp. 1932;50:137-195.
    1. Ragnarsson O, Johannsson G. Cushing's syndrome: a structured short- and long-term management plan for patients in remission. Eur J Endocrinol. 2013;169(5):R139-R152.
    1. Papakokkinou E, Olsson DS, Chantzichristos D, et al. Excess morbidity persists in patients with Cushing's disease during long-term remission: a Swedish nationwide study. J Clin Endocrinol Metab. 2020;105(8):2616-2624.
    1. Bengtsson D, Ragnarsson O, Berinder K, et al. Psychotropic drugs in patients with Cushing's disease before diagnosis and at long-term follow-up: a nationwide study. J Clin Endocrinol Metab. 2021;106(6):1750-1760.
    1. Schernthaner-Reiter MH, Siess C, Gessl A, et al. Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission. Endocrine. 2019;64(1):157-168.

LinkOut - more resources